This HTML5 document contains 36 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB09021/identifier/wikipedia/
n8http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n6http://linked.opendata.cz/resource/drugbank/patent/
n10http://linked.opendata.cz/resource/drugbank/drug/DB09021/identifier/kegg-drug/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n12http://linked.opendata.cz/resource/drugbank/drug/DB09021/identifier/drugbank/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB09021
rdf:type
n3:Drug
n3:description
Benzoctamine is a drug that possesses sedative and anxiolytic properties. It is different from most sedative drugs because in most clinical trials it does not produce respiratory depression, but actually stimulates the respiratory system. Benzoctamine has been found to have the same efficacy as chlordiazepoxide when treating anxiety neurosis.
n3:generalReferences
# Lippmann W, Pugsley TA: Effects of benzoctamine and chlordiazepoxide on turnover and uptake of 5-hydroxytryptamine in the brain. Br J Pharmacol. 1974 Aug;51(4):571-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/4480288
n3:group
approved
n3:halfLife
2 to 3 hours.
owl:sameAs
n8:DB09021
dcterms:title
Benzoctamine
adms:identifier
n10:D03089 n11:Benzoctamine n12:DB09021
n3:patent
n6:3399201
n3:synonym
N-Methyl-9,10-ethanoanthracene-9(10H)-methanamine
n3:salt
n3:synthesisReference
U.S. Patent 3,399,201.
n3:IUPAC-Name
n4:271B3E81-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B3E7F-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B3E7D-363D-11E5-9242-09173F13E4C5 n4:271B3E80-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B3E7E-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:N05BD01
n3:H-Bond-Acceptor-Count
n4:271B3E87-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B3E88-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B3E83-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B3E85-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B3E84-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B3E86-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
10085-81-1
n3:Bioavailability
n4:271B3E8C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B3E8E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B3E8F-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B3E90-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B3E8B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B3E8A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B3E8D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B3E82-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B3E89-363D-11E5-9242-09173F13E4C5